TrialCompass™ TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06494371

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing LCAR-HL30 cells for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

LCAR-HL30 cells (BIOLOGICAL): Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine

Drugs / treatments
LCAR-HL30 cells
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

NCT06494371

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing LCAR-HL30 cells for people whose anaplastic large cell lymphoma (ALCL) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 75 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)

What's being tested

LCAR-HL30 cells (BIOLOGICAL): Prior to infusion of the LCAR-HL30, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine

Drugs / treatments: LCAR-HL30 cells

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 32 patients

Primary endpoint: Incidence, severity, and type of treatment-emergent adverse events (TEAEs); Pharmacokinetics in peripheral blood; Pharmacokinetics in peripheral blood; Pharmacokinetics in bone marrow; Pharmacokinetics in bone marrow; Recommended Phase 2 Dose (RP2D) regimen finding

Ages: 18 Years to 75 Years

Start date: 2024-07 | Est. completion: 2028-08

Locations

0 US sites · 1 total

Contact

Jianqing Mi | jianqingmi@shsmu.edu.cn | 13524488296

Sponsor: Ruijin Hospital (OTHER)

Tags

ALCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06494371

Prepared using TrialCompass (trialcompass.com) on July 4, 2026. For informational purposes only. Always discuss with your healthcare team.